Business Context and Reporting Period
Company: Therapix Biosciences Ltd. (Note: Input metadata referenced "Scisparc Ltd.", but the filing text identifies the registrant as Therapix Biosciences Ltd.)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2016
Jurisdiction: Israel (Incorporated August 23, 2004)
Listing: Ordinary Shares on Tel Aviv Stock Exchange (TASE); American Depositary Shares (ADSs) on NASDAQ Capital Market (commenced trading March 22, 2017).
Business Overview: A clinical-stage pharmaceutical company focused on repurposing FDA-approved synthetic cannabinoids (dronabinol). Key programs include THX-TS01 for Tourette Syndrome (TS) and THX-ULD01 for Mild Cognitive Impairment (MCI). The company has no commercial revenue and relies on equity financing.
Key Financial Metrics (Year Ended Dec 31, 2016)
| Metric | 2016 (NIS '000s) | 2016 (USD '000s)* | 2015 (NIS '000s) |
|---|---|---|---|
| Revenues | 0 | 0 | 0 |
| Research & Development Expenses | 2,842 | 739 | 931 |
| General & Administrative Expenses | 4,870 | 1,267 | 5,297 |
| Operating Loss | (7,682) | (1,999) | (9,962) |
| Net Comprehensive Loss | (7,728) | (2,010) | (10,164) |
| Cash and Cash Equivalents | 2,598 | 676 | 6,136 |
| Total Assets | 4,788 | 1,245 | 6,501 |
| Accumulated Deficit | (121,124) | (31,502) | (113,468) |
| Total Equity (Deficit) | 2,203 | 573 | 5,114 |
*USD amounts are convenience translations based on the exchange rate of NIS 3.845 to $1.00 as of Dec 31, 2016.
Material Changes vs. Prior Period
- Operating Loss Reduction: Operating loss decreased by 22.9% (NIS 2.28 million) compared to 2015, primarily due to a decrease in General and Administrative (G&A) expenses.
- R&D Increase: R&D expenses increased by 205% (NIS 1.91 million) year-over-year, driven by increased consulting/subcontractor fees and wages related to clinical trial preparations for cannabinoid projects.
- G&A Decrease: G&A expenses decreased by 8% (NIS 0.43 million), mainly due to lower office maintenance and rent costs.
- Cash Position: Cash and cash equivalents declined significantly from NIS 6.1 million in 2015 to NIS 2.6 million in 2016. Net cash used in operating activities was NIS 5.7 million.
- Share Count: The number of ordinary shares used in computing loss per share increased to 37.5 million in 2016 from 23.9 million in 2015.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Liquidity
Management expects existing cash resources (including funds raised in a March 2017 offering) to fund operations through at least June 30, 2018. The company anticipates incurring significant losses until product commercialization, which may not occur for several years. Substantial additional capital will be required to complete clinical development and commercialization.
Management Commentary
- Clinical Progress: Initiated a Phase IIa proof-of-concept trial for THX-TS01 (Tourette Syndrome) in the US in late 2016. Plans to initiate a Phase IIb trial in Europe in Q3 2017. A Phase I trial for THX-ULD01 (MCI) is planned for Q2 2017.
- Regulatory Strategy: Intends to seek FDA approval via the Section 505(b)(2) pathway. An orphan drug designation request for THX-TS01 was held in abeyance by the FDA pending additional data on TS prevalence.
Risks and Contingencies
- Regulatory Sanctions: In April 2017, the company settled an administrative inquiry with the Israel Securities Authority (ISA) regarding disclosure failures related to a 2014 license termination. The company paid a NIS 150,000 sanction and admitted to breaches. The Chairman is subject to a one-year probationary condition.
- Capital Requirements: Failure to secure additional funding could force the company to delay, limit, or terminate development programs.
- Intellectual Property: Reliance on licensed patents and trade secrets; risk of third-party infringement claims or inability to enforce rights.
- Geopolitical Risk: Operations are based in Israel, exposing the company to regional political, economic, and military instability.
- Controlled Substances: Product candidates contain dronabinol (Schedule I controlled substance), requiring DEA rescheduling before marketing.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the NIS 2.6 million cash balance (plus March 2017 proceeds) to fund operations through mid-2018 given the high burn rate.
- ISA Settlement Impact: Assess the implications of the ISA settlement and the Chairman's probationary status on corporate governance and future regulatory compliance.
- Clinical Trial Status: Confirm the enrollment and progress of the THX-TS01 Phase IIa trial and the timeline for the THX-ULD01 Phase I trial.
- Orphan Drug Designation: Monitor the status of the FDA's request for additional data regarding the orphan drug designation for Tourette Syndrome.
- Related Party Transactions: Review the terms of the license agreement with Dekel (controlled by the Chairman) and the potential for future conflicts of interest.
- IIA Grant Obligations: Verify compliance with Israeli Innovation Authority (IIA) grant terms regarding royalties and technology transfer restrictions.